GLP-1 medication like Wegovy and Zepbound have been racking up gross sales and new indications, as researchers study extra about how the medication have an effect on the physique past simply weight reduction.
However one of many extra anticipated research exploring how they affect Alzheimer’s illness has discovered no significant impact, Novo Nordisk stated in a press launch on Nov. 24
The corporate, which makes semaglutide (bought as Wegovy for weight reduction and Ozempic for diabetes), stated that its drug didn’t present any extra profit over placebo in two trials of individuals with early Alzheimer’s. The corporate is planning to launch extra information at a presentation on the Medical Trials on Alzheimer’s Illness convention in early December and on the Alzheimer’s and Parkinson’s Ailments conferences in March 2026.
The 2-year examine included greater than 3,800 folks with delicate cognitive impairment or delicate dementia as a result of Alzheimer’s, half of whom had been randomly assigned to take a semaglutide tablet every single day, and half of whom took placebo. The corporate stated that folks receiving the drug did present enhancements in sure organic measures of Alzheimer’s illness, however that these modifications didn’t translate into slower illness development as measured by a regular check of a number of areas of cognitive capability, together with reminiscence, downside fixing, sociability, and self-care. Specialists are ready for extra detailed information on the outcomes to know whether or not the enhancements in markers of the illness might be early indicators of potential profit, particularly if mixed with different methods like conduct modifications and at present accessible drugs.
Learn Extra: The Heavy Value of Utilizing Weight-Loss Medicine to Get Skinny
Researchers had been hopeful that the weight-loss medication may have an effect on Alzheimer’s, since irritation contributes to the neurodegenerative illness and the medication appear to have an anti-inflammatory impact. Research in animal fashions, in addition to observational research of individuals taking the drug to deal with diabetes or weight acquire, hinted that the drug could gradual the advance of Alzheimer’s.
New Alzheimer’s remedies are wanted, since at present solely two—lecanemab (from Eisai) and donanemab (from Lilly)—tackle the basis causes of Alzheimer’s. Each work by attacking the buildup of amyloid plaques within the mind and might gradual illness development by as much as 30% for folks with mild-to-moderate illness. “These outcomes will assist us refine our understanding of this class of medicine,” stated Maria Carrillo, chief science officer and medical affairs lead for the Alzheimer’s Affiliation, in a assertion. “Although this semaglutide tablet didn’t assist in opposition to Alzheimer’s, the sector will proceed to analyze this class of medicine, as they could act in another way.”
Eli Lilly, which makes the opposite drug within the class, tirzepatide, has not stated whether or not it plans to check its product’s impact on Alzheimer’s.
Novo Nordisk stated it could discontinue a deliberate one-year comply with up of the folks within the trials.
